Argenx SE/ NL0010832176 /
11/10/2024 14:28:58 | Chg. -14.85 | Volume | Bid04/10/2024 | Ask25/07/2024 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
476.50EUR | -3.02% | 23 Turnover: 10,959.50 |
-Bid Size: - | -Ask Size: - | 28.77 bill.EUR | - | - |
GlobeNewswire
26/08
MDA Kicks Off Muscular Dystrophy Awareness Month in September with ‘30 Days of Strength’ Campaign wi...
GlobeNewswire
12/08
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire
25/07
argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update
GlobeNewswire
18/07
argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 202...
GlobeNewswire
16/07
argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Ge...
GlobeNewswire
25/06
argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 P...
GlobeNewswire
21/06
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropat...
GlobeNewswire
17/06
argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcomi...
GlobeNewswire
13/06
Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors
GlobeNewswire
09/05
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
02/05
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
GlobeNewswire
16/04
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Pa...
GlobeNewswire
27/03
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
GlobeNewswire
26/03
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thr...
GlobeNewswire
07/03
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of ...
GlobeNewswire
29/02
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update